AMGN AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert Bradway
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMGEN
SEC CIK
Corporate docs
IRS number
953540776
AMGN stock data
()
News
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
16 Apr 21
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
16 Apr 21
Is Silicon Valley Replacing Big Pharma In Neuroscience?
6 Apr 21
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $275
5 Apr 21
The Latest Picks And Pans From Barron's: Barrick Gold, BioNTech, Facebook, WW And More
4 Apr 21
Press releases
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
16 Apr 21
Amgen to Acquire Rodeo Therapeutics Corporation
30 Mar 21
Controlling Inflammation to Stop Disease
24 Mar 21
FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX
11 Mar 21
Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference
11 Mar 21
Calendar
8 Feb 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from AMGEN earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.27B | 6.27B | 6.27B | 6.27B | 6.27B | 6.27B |
Cash burn (monthly) | 940.33M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 3.39B | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 2.88B | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 3.1 | n/a | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Apr 21 | Ronald D Sugar | Common Stock | Sell | Dispose S | No | Yes | 249.98 | 1,000 | 249.98K | 15,927 |
14 Apr 21 | Ronald D Sugar | Common Stock | Option exercise | Aquire M | No | No | 71.64 | 1,000 | 71.64K | 16,927 |
14 Apr 21 | Ronald D Sugar | Nqso Common Stock | Option exercise | Dispose M | No | No | 71.64 | 1,000 | 71.64K | 1,000 |
19 Mar 21 | Robert A Bradway | Common Stock | Payment of exercise | Dispose F | No | No | 244.42 | 21,190 | 5.18M | 589,262 |
19 Mar 21 | Gordon Murdo | Common Stock | Payment of exercise | Dispose F | No | No | 244.42 | 8,989 | 2.2M | 41,458 |
19 Mar 21 | Jonathan P Graham | Common Stock | Payment of exercise | Dispose F | No | No | 244.42 | 4,360 | 1.07M | 44,529 |
19 Mar 21 | Nancy A. Grygiel | Common Stock | Payment of exercise | Dispose F | No | No | 244.42 | 435 | 106.32K | 12,051 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
76.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 2139 |
Opened positions | 236 |
Closed positions | 175 |
Increased positions | 876 |
Reduced positions | 748 |
13F shares |
Current |
---|---|
Total value | 101.49B |
Total shares | 437.38M |
Total puts | 4.08M |
Total calls | 3.65M |
Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 47.81M | $10.99B |
Vanguard | 47.23M | $10.86B |
Capital Research Global Investors | 31.76M | $7.3B |
STT State Street | 30.09M | $6.92B |
Primecap Management | 16.98M | $3.9B |
FMR | 13.78M | $3.17B |
MS Morgan Stanley | 9.75M | $2.24B |
Geode Capital Management | 8.8M | $2.02B |
NTRS Northern Trust | 7.92M | $1.82B |
WFC Wells Fargo & Co. | 7.61M | $1.75B |
Financial report summary
?Competition
Celgene • Novelion Therapeutics • Spectrum Pharmaceuticals • Geron • Roche • Nektar Therapeutics • FibroGen • Exelixis • Sangamo Therapeutics • Protalix BioTherapeuticsContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AABP, AAER, accident, AECP, aflibercept, AISN, ALEN, Allergy, Alliance, ambition, AMD, AMP, amplify, amy, andChief, antibribery, anticorruption, antikickback, antiresorptive, arrive, Arthrex, autumn, AVEN, avoid, avoided, AVSOLA, backdoor, background, backlog, BARDA, BEIJERINCK, Biden, Biomedical, black, Blaylock, blended, BNP, body, BofA, bond, boosting, border, broadened, BSA, Businesswomen, calcimimetic, Career, Chinese, Cir, clarification, clear, coalition, CodeBreaK, cohort, college, combat, compulsory, concurrently, Connecticut, constitutionality, coordinated, copay, COVID, Crohn, culture, curfew, cutoff, cybersecurity, daily, deal, deceleration, dedesignate, deeper, Deficiency, defray, degeneration, dental, deplete, Deutsche, diagnosed, diminish, disciplined, dissemination, distancing, docetaxel, downturn, ease, ebb, ecosystem, edema, elderly, emphasize, Empowered, encompassing, endothelial, enduring, England, exacerbated, exacerbation, exempted, EYLEA, Fc, featured, Fed, fell, fleet, fluidity, foreseeable, foster, futility, globe, goal, Grygiel, Hampshire, healthy, HGRAC, HIV, hospital, hospitalized, ICOSL, ICS, IIIB, immune, immunodeficiency, immunosuppressive, impossible, incentivize, incident, Indian, inhaled, injury, inserted, instructing, intelligence, interfering, interlocutory, intermittent, internet, investee, joinder, Journal, KANJINTI, learning, left, legitimate, LGBTQ, linda, lockdown, logistical, louie, lp, macular, magnitude, makeup, manipulated, Maryland, MBA, medium, MFN, microscopic, mind, Minnesota, mission, mobile, motivate, motivating, multicenter, myriad, Nancy, nationwide, navigable, navigate, NAVIGATOR, NDA, neovascular, Nephew, neutrality, NIAID, nonbiologic, nonfederal, NYVEPRIA, occlusion, occupancy, OCS, OECD, Olpasiran, OneTen, onset, ORR, outbreak, output, outreach, overcome, overseen, pandemic, PASI, paused, pausing, physically, portal, postmarketing, precipitate, precipitated, prepaid, prepandemic, PRIDE, proliferation, proportion, proportionate, protocol, Purple, pushed, quartile, RBC, reassessment, recession, recommenced, redemption, reimpose, remote, remotely, renamed, representation, resource, respiratory, resurgence, resurgent, retaliatory, retinal, retinopathy, reverification, reward, rheumatology, RIABNITM, RINVOQ, RNA, root, RTOR, School, score, semiannual, Shank, Siebert, signification, siRNA, Smith, SoC, softened, sotorasib, speaker, sPGA, spread, Stafford, stakeholder, static, STELARA, Stivarga, strain, Subcontinent, surface, surge, tackle, talent, TBA, temperature, threat, timeline, Tokyo, training, trajectory, transmission, travel, turnover, UCLA, UDENYCA, unamortized, underemployment, underrepresentation, unemployment, uninsured, ustekinumab, vaccination, Van, vascular, VEGFR, vein, verified, virtual, Warehouse, Wegener, wet, wider, winter, workplace, writ, Xeljanz
Removed:
AAA, advisory, Alzheimer, amyloid, atopic, augment, BACE, BLA, cardiac, construing, Cynthia, damage, decided, deCODE, deducting, Dermatology, Dezima, discontinuation, footprint, force, Galenica, Genentech, genome, grew, henderson, hold, Hope, hyperparathyroidism, impacting, Leonard, lessen, lesser, loan, margin, meline, Merck, Mimpara, MIRCERA, moot, moved, mutually, myosin, narrow, noncompliance, overhaul, pain, patentability, Patton, presidential, PROCRIT, properly, propose, reacquired, rebecca, reshaping, retained, revalue, SCAN, Schaeffer, sector, Servier, showing, sNDA, sorafenib, threshold, track, validation, vitamin
Financial reports
10-K
2020 FY
Annual report
8 Feb 21
10-Q
2020 Q3
Quarterly report
28 Oct 20
10-Q
2020 Q2
Quarterly report
28 Jul 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K/A
2019 FY
Annual report (amended)
13 Feb 20
10-K
2019 FY
Annual report
12 Feb 20
10-Q
2019 Q3
Quarterly report
29 Oct 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
30 Apr 19
10-K
2018 FY
Annual report
13 Feb 19
Current reports
8-K
Amgen Successfully Completes Acquisition of Five Prime Therapeutics
16 Apr 21
8-K
Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide
4 Mar 21
8-K
Amgen Reports Fourth Quarter and Full Year 2020 Financial Results
2 Feb 21
8-K
Amgen Reports Third Quarter 2020 Financial Results
28 Oct 20
8-K
Entry into a Material Definitive Agreement
17 Aug 20
8-K
Amgen Announces Early Tender Results
13 Aug 20
8-K
Other Events
30 Jul 20
8-K
Amgen Reports Second Quarter 2020 Financial Results
28 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
16 Apr 21
424B3
Prospectus supplement
15 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
8 Apr 21
S-4/A
Registration of securities issued in business combination transactions (amended)
6 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
6 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 21
SC TO-T
Third party tender offer statement
18 Mar 21
SC TO-C
Information about tender offer
5 Mar 21
SC TO-C
Information about tender offer
4 Mar 21
SC TO-C
Information about tender offer
4 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEFA14A
Additional proxy soliciting materials
6 Apr 21
DEF 14A
Definitive proxy
6 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
PX14A6G
Letter to shareholders
15 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
13 May 19
Other
EFFECT
Notice of effectiveness
16 Apr 21
CT ORDER
Confidential treatment order
24 Oct 19
CT ORDER
Confidential treatment order
3 Jun 19
CT ORDER
Confidential treatment order
30 May 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
3 Dec 17
CT ORDER
Confidential treatment order
7 Sep 17
CT ORDER
Confidential treatment order
14 Aug 17
CT ORDER
Confidential treatment order
25 May 17
CT ORDER
Confidential treatment order
7 May 17
Ownership
4
AMGEN / RONALD D SUGAR ownership change
15 Apr 21
4
AMGEN / Esteban Santos ownership change
22 Mar 21
4
AMGEN / DAVID M REESE ownership change
22 Mar 21
4
AMGEN / David Piacquad ownership change
22 Mar 21
4
AMGEN / Linda H. Louie ownership change
22 Mar 21
4
AMGEN / Lori A Johnston ownership change
22 Mar 21
4
AMGEN / Nancy A. Grygiel ownership change
22 Mar 21
4
AMGEN / Jonathan P Graham ownership change
22 Mar 21
4
AMGEN / Murdo Gordon ownership change
22 Mar 21
4
AMGEN / Robert A Bradway ownership change
22 Mar 21
Patents
APP
Utility
Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
8 Apr 21
Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided.
APP
Utility
INTERLEUKIN-2 Muteins for the Expansion of T-regulatory Cells
1 Apr 21
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production.
APP
Utility
Method for Making Injectable Pharmaceutical Compositions
1 Apr 21
The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.
APP
Utility
Pacap Antibodies and Uses Thereof
1 Apr 21
The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies.
APP
Utility
Formulations of (+)-2-[1-(3-ETHOXY-4- METHOXY-PHENYL)-2-METHANESULFONYL- ETHYL]-4-ACETYLAMINOISOINDOLINE-1,3- Dione
1 Apr 21
Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein.
Transcripts
2020 Q4
Earnings call transcript
3 Feb 21
2020 Q3
Earnings call transcript
28 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
1 May 20
2019 Q4
Earnings call transcript
30 Jan 20
2019 Q3
Earnings call transcript
29 Oct 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
30 Apr 19
2018 Q4
Earnings call transcript
29 Jan 19
2018 Q3
Earnings call transcript
30 Oct 18
Reddit threads
Explain Dividends
16 Apr 21
SCHD. I love their growth but I question if a few of their holdings can maintain that performance. My question is, does the ETF have the ability to adjust their holdings by making adjustments with underperformers?
14 Apr 21
NVIDIA Announces CPU for Giant AI and High Performance Computing Workloads
12 Apr 21
ATNF finally set for a big Short Squeeze on Monday.. and a couple of false starts.. Friday finally held above $9.50 for the first time.
10 Apr 21
Weekly Advice and Earnings Megathread
9 Apr 21
ATNF Short Squeeze may jump tmrw & best management team in entire Biotech industry.
8 Apr 21
Who’s going long on Pfizer (PFE)?
7 Apr 21
Investing in dividends while young | please critique my narrative
6 Apr 21
Long term stocks
4 Apr 21
Healthcare Growth stocks
3 Apr 21